Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

Immix Biopharma, Inc. (NASDAQ:IMMX) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 470,700 shares, a growth of 17.5% from the November 15th total of 400,700 shares. Currently, 2.9% of the shares of the company are sold short. Based on an average daily trading volume, of 159,400 shares, the short-interest ratio is presently 3.0 days.

Institutional Investors Weigh In On Immix Biopharma

An institutional investor recently bought a new position in Immix Biopharma stock. Invst LLC bought a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned about 0.10% of Immix Biopharma as of its most recent filing with the Securities & Exchange Commission. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Immix Biopharma in a research report on Thursday, October 3rd.

Immix Biopharma Price Performance

Shares of IMMX stock traded up $0.05 during trading hours on Monday, reaching $2.09. 75,410 shares of the company’s stock were exchanged, compared to its average volume of 184,148. The company’s 50 day moving average is $1.78 and its two-hundred day moving average is $1.93. The company has a market cap of $57.49 million, a P/E ratio of -2.47 and a beta of 0.28. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $7.75.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). As a group, analysts predict that Immix Biopharma will post -0.64 EPS for the current fiscal year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.